98 related articles for article (PubMed ID: 24000664)
21. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
Masson V
Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
[TBL] [Abstract][Full Text] [Related]
22. [The clinical prospects for the study of the plasminogen activation system in breast cancer].
Gershteĭn ES; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 1999; (8):58-61. PubMed ID: 10487126
[TBL] [Abstract][Full Text] [Related]
23. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer.
Takeuchi T; Hisanaga M; Nagao M; Ikeda N; Fujii H; Koyama F; Mukogawa T; Matsumoto H; Kondo S; Takahashi C; Noda M; Nakajima Y
Clin Cancer Res; 2004 Aug; 10(16):5572-9. PubMed ID: 15328199
[TBL] [Abstract][Full Text] [Related]
24. Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells--associations with histopathology and patients outcome.
Jensen SA; Vainer B; Bartels A; Brünner N; Sørensen JB
Eur J Cancer; 2010 Dec; 46(18):3233-42. PubMed ID: 20801641
[TBL] [Abstract][Full Text] [Related]
25. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
26. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
27. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinases in colorectal cancer.
Mysliwiec AG; Ornstein DL
Clin Colorectal Cancer; 2002 Feb; 1(4):208-19. PubMed ID: 12450419
[TBL] [Abstract][Full Text] [Related]
30. mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay.
Ramón L; Gilabert-Estellés J; Castelló R; Gilabert J; España F; Romeu A; Chirivella M; Aznar J; Estellés A
Hum Reprod; 2005 Jan; 20(1):272-8. PubMed ID: 15579491
[TBL] [Abstract][Full Text] [Related]
31. Effects of nicotine and lipopolysaccharide on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in human osteoblasts.
Katono T; Kawato T; Tanabe N; Tanaka H; Suzuki N; Kitami S; Morita T; Motohashi M; Maeno M
Arch Oral Biol; 2009 Feb; 54(2):146-55. PubMed ID: 18986645
[TBL] [Abstract][Full Text] [Related]
32. Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems.
Krol J; Sato S; Rettenberger P; Assfalg-Machleidt I; Schmitt M; Magdolen V; Magdolen U
Biol Chem; 2003 Jul; 384(7):1085-96. PubMed ID: 12956425
[TBL] [Abstract][Full Text] [Related]
33. Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells.
Lee SK; Han YM; Yun J; Lee CW; Shin DS; Ha YR; Kim J; Koh JS; Hong SH; Han DC; Kwon BM
Int J Cancer; 2012 Aug; 131(3):E190-203. PubMed ID: 22131018
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems.
Krol J; Kopitz C; Kirschenhofer A; Schmitt M; Magdolen U; Krüger A; Magdolen V
Biol Chem; 2003 Jul; 384(7):1097-102. PubMed ID: 12956426
[TBL] [Abstract][Full Text] [Related]
36. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
37. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
Emenaker NJ; Basson MD
J Surg Res; 1998 Apr; 76(1):41-6. PubMed ID: 9695737
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Curran S; Dundas SR; Buxton J; Leeman MF; Ramsay R; Murray GI
Clin Cancer Res; 2004 Dec; 10(24):8229-34. PubMed ID: 15623598
[TBL] [Abstract][Full Text] [Related]
39. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
40. [Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal neoplasm].
Wan Y; Wei Q; Pan Y; Liu Y
Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):510-3. PubMed ID: 11832095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
